Skip to main content

Urinary Tract Infection Bacterial

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Inmunotek
InmunotekSpain - Madrid
1 program
1
MV140Phase 31 trial
Active Trials
NCT02543827Completed240Est. Dec 2020
United Therapeutics
United TherapeuticsMD - Silver Spring
1 program
Bacteriophage TherapyPHASE_1_21 trial
Active Trials
NCT04287478Terminated1Est. Feb 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
InmunotekMV140
United TherapeuticsBacteriophage Therapy

Clinical Trials (2)

Total enrollment: 241 patients across 2 trials

Evaluation of the Efficacy and Safety of MV140

Start: Nov 2015Est. completion: Dec 2020240 patients
Phase 3Completed
NCT04287478United TherapeuticsBacteriophage Therapy

Bacteriophage Therapy in Patients With Urinary Tract Infections

Start: Dec 2020Est. completion: Feb 20231 patients
Phase 1/2Terminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.